中药对盆腔子宫内膜异位症盆腔状况的影响及作用机制研究
|
摘要
研究目的
本研究以回顾性分析术前应用中药治疗对盆腔子宫内膜异位症患者盆腔状况的影响作为研究背景,在此基础上进行前瞻性研究,通过观察莪棱胶囊治疗30例气滞血瘀型盆腔内异症患者的临床疗效,比较治疗前后患者血清中可溶性细胞间粘附分子-1(sICAM-1)、血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)、白细胞介素-6(IL-6)含量的变化,从“3A”(粘附、侵袭、血管形成)及免疫方面,探讨中药应用对盆腔子宫内膜异位症盆腔状况影响的作用机制,为今后围手术期应用中药提供初步理论依据。
研究方法
1.回顾性研究
收集2005年1月1日～2007年12月31日在广东省中医院妇科住院行手术治疗的盆腔子宫内膜异位症(经手术治疗及病理证实)患者133例,根据术前治疗情况分为中药组和空白组,对其住院病历进行回顾性分析,按照美国生育协会修订的子宫内膜异位症分期(r-AFS)法标准,分别对两组患者进行r-AFS评分,了解术前中药应用对盆腔状况的影响。
2.前瞻性研究
收集2007年2月～2008年2月期间在我院内异症专科门诊就诊,并符合纳入标准的气滞血瘀型盆腔子宫内膜异位症病例30例,给予莪棱胶囊治疗3个月,观察莪棱胶囊治疗的临床疗效,比较治疗前后患者血清中可溶性细胞间粘附分子-1(sICAM-1)、血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)、白细胞介素-6(IL-6)的含量变化,从“3A”及免疫机制方面,探讨中药对盆腔子宫内膜异位症盆腔状况影响的作用机制。
研究结果
1.在回顾性研究中,手术中发现中药组患者r-AFS评分为41.94±25.62分,空白组55.79±31.67分,两组的r-AFS评分比较具有显著性差异(P＜0.05),表明中药组患者的r-AFS评分较空白组低。
2.在前瞻性研究中,经莪棱胶囊治疗3个月后,气滞血瘀型盆腔内异症患者的痛经症状得到明显改善,痛经积分较前降低,治疗前后比较有显著性差异(P＜0.05);患者全身及局部的血瘀症状亦得到显著改善(P＜0.05);盆腔包块亦较治疗前缩小(P＜0.05),临床治疗总有效率达83.3%。
3.莪棱胶囊治疗3个月后,能够降低气滞血瘀型盆腔内异症患者血清中的sICAM-1、MMP-9和IL-6水平,与治疗前同期比较,均有显著性差异(P＜0.05);治疗后患者血清中的VEGF水平与治疗前同期比较,差异无统计学意义(P＞0.05)。
结论
1.通过回顾性研究,发现术前应用中药治疗能够降低盆腔内异症患者的r-AFS评分,与术前没有经过药物治疗的空白组相比,中药疗法可使盆腔粘连与腹膜异位病灶减少,通过改善盆腔环境,使手术顺利进行。
2.莪棱胶囊治疗气滞血瘀型盆腔内异症具有良好的临床疗效,不仅有效缓解患者的痛经症状、改善机体的瘀血状态,而且能够缩小卵巢子宫内膜异位囊肿,对控制疾病的进展起到重要作用。
3.莪棱胶囊可降低气滞血瘀型盆腔内异症患者血清中slCAM-1、MMP-9及IL-6的水平,推测中药应用可通过调节患者的体液和细胞免疫功能、阻断EM发生的“3A(粘附、侵袭、血管形成)”病理环节,影响疾病的形成和进展,从而达到改善盆腔状况的作用。
Objectives:
The effect on pelvic cavities of patient with pelvic endometriosis treated with Traditional Chinese Medicine Virtual Screening before operation were analyzed retrospectively.In this research background,to study the clinical effect of TCM therapy,and the variation of sICAM-1,VEGF、MMP-9、IL-6 expression in serum of patients with pelvic endometriosis.Reasearch on the pelvic cavities of patients with pelvic endometriosis treated with TCM preoperatively and its mechanisms of"3A"and immunity.
Methods:
1.Background research
There were 133 cases with pelvic endometriosis,which were confirmed by surgery and pathology,receiving surgical treatment in Guangdong provincial TCM hospital from 2005 to 2007.Reasearch on the pelvic cavities of patients with pelvic endometriosis treated with TCM preoperatively.
2.prospective study
There were 30 cases with pelvic endometriosis treated with TCM treatment in special clinic of endometriosis in Guangdong provincial TCM hospital from February of 2007 to February of 2008.To study the variation of sICAM-1, VEGF、MMP-9、IL-6 expression in serum of patients,who received TCM treatment for 3 months,and then used the statistical software SPSS13.0 editions for the statistical analysis.
Results: @
1.In Background research,we foud that r-AFS score in the TCM group is 41.94±25.62,lower than the group without treatment preoperative,which is 55.79±31.67.There was statistical difference between the r-AFS score. @
2.The Painful menstruation and the blood stasis symptom of 30 patients with pelvic endometriosis were reduced after TCM treatment.The dysmenorrheal score is lower then before.There was significant statistical difference between the two(P＜0.05). @
3.The expression of sICAM-1,VEGF、MMP-9、IL-6 in serum of patients with pelvic endometriosis were decreased after treatment with TCM for 3 months.There was statistical difference between the two(P＜0.05).But there was no statistical difference as compared with VEGF in the serum pre and post treatment(P＞0.05). @
Conclusion: @
1.The r-AFS score in the patients with pelvic endometriosis could be reduced by the treatment with Traditional Chinese Medicine Virtual Screening preoperatively,in these station,operation could be done successfully. @
2.The Painful menstruation and the blood stasis symptom of the patients with pelvic endometriosis could be improved with the TCM treatment. @
3.The expression of sICAM-1,VEGF,MMP-9,IL-6 in serum of patients with pelvic endometriosis were decreased after TCM treatment.We conjecture that mechanisms of TCM treatment on the patients with pelvic endometriosis,is concern with the 3A" and immunity.
本研究以回顾性分析术前应用中药治疗对盆腔子宫内膜异位症患者盆腔状况的影响作为研究背景,在此基础上进行前瞻性研究,通过观察莪棱胶囊治疗30例气滞血瘀型盆腔内异症患者的临床疗效,比较治疗前后患者血清中可溶性细胞间粘附分子-1(sICAM-1)、血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)、白细胞介素-6(IL-6)含量的变化,从“3A”(粘附、侵袭、血管形成)及免疫方面,探讨中药应用对盆腔子宫内膜异位症盆腔状况影响的作用机制,为今后围手术期应用中药提供初步理论依据。
研究方法
1.回顾性研究
收集2005年1月1日～2007年12月31日在广东省中医院妇科住院行手术治疗的盆腔子宫内膜异位症(经手术治疗及病理证实)患者133例,根据术前治疗情况分为中药组和空白组,对其住院病历进行回顾性分析,按照美国生育协会修订的子宫内膜异位症分期(r-AFS)法标准,分别对两组患者进行r-AFS评分,了解术前中药应用对盆腔状况的影响。
2.前瞻性研究
收集2007年2月～2008年2月期间在我院内异症专科门诊就诊,并符合纳入标准的气滞血瘀型盆腔子宫内膜异位症病例30例,给予莪棱胶囊治疗3个月,观察莪棱胶囊治疗的临床疗效,比较治疗前后患者血清中可溶性细胞间粘附分子-1(sICAM-1)、血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)、白细胞介素-6(IL-6)的含量变化,从“3A”及免疫机制方面,探讨中药对盆腔子宫内膜异位症盆腔状况影响的作用机制。
研究结果
1.在回顾性研究中,手术中发现中药组患者r-AFS评分为41.94±25.62分,空白组55.79±31.67分,两组的r-AFS评分比较具有显著性差异(P＜0.05),表明中药组患者的r-AFS评分较空白组低。
2.在前瞻性研究中,经莪棱胶囊治疗3个月后,气滞血瘀型盆腔内异症患者的痛经症状得到明显改善,痛经积分较前降低,治疗前后比较有显著性差异(P＜0.05);患者全身及局部的血瘀症状亦得到显著改善(P＜0.05);盆腔包块亦较治疗前缩小(P＜0.05),临床治疗总有效率达83.3%。
3.莪棱胶囊治疗3个月后,能够降低气滞血瘀型盆腔内异症患者血清中的sICAM-1、MMP-9和IL-6水平,与治疗前同期比较,均有显著性差异(P＜0.05);治疗后患者血清中的VEGF水平与治疗前同期比较,差异无统计学意义(P＞0.05)。
结论
1.通过回顾性研究,发现术前应用中药治疗能够降低盆腔内异症患者的r-AFS评分,与术前没有经过药物治疗的空白组相比,中药疗法可使盆腔粘连与腹膜异位病灶减少,通过改善盆腔环境,使手术顺利进行。
2.莪棱胶囊治疗气滞血瘀型盆腔内异症具有良好的临床疗效,不仅有效缓解患者的痛经症状、改善机体的瘀血状态,而且能够缩小卵巢子宫内膜异位囊肿,对控制疾病的进展起到重要作用。
3.莪棱胶囊可降低气滞血瘀型盆腔内异症患者血清中slCAM-1、MMP-9及IL-6的水平,推测中药应用可通过调节患者的体液和细胞免疫功能、阻断EM发生的“3A(粘附、侵袭、血管形成)”病理环节,影响疾病的形成和进展,从而达到改善盆腔状况的作用。
Objectives:
The effect on pelvic cavities of patient with pelvic endometriosis treated with Traditional Chinese Medicine Virtual Screening before operation were analyzed retrospectively.In this research background,to study the clinical effect of TCM therapy,and the variation of sICAM-1,VEGF、MMP-9、IL-6 expression in serum of patients with pelvic endometriosis.Reasearch on the pelvic cavities of patients with pelvic endometriosis treated with TCM preoperatively and its mechanisms of"3A"and immunity.
Methods:
1.Background research
There were 133 cases with pelvic endometriosis,which were confirmed by surgery and pathology,receiving surgical treatment in Guangdong provincial TCM hospital from 2005 to 2007.Reasearch on the pelvic cavities of patients with pelvic endometriosis treated with TCM preoperatively.
2.prospective study
There were 30 cases with pelvic endometriosis treated with TCM treatment in special clinic of endometriosis in Guangdong provincial TCM hospital from February of 2007 to February of 2008.To study the variation of sICAM-1, VEGF、MMP-9、IL-6 expression in serum of patients,who received TCM treatment for 3 months,and then used the statistical software SPSS13.0 editions for the statistical analysis.
Results: @
1.In Background research,we foud that r-AFS score in the TCM group is 41.94±25.62,lower than the group without treatment preoperative,which is 55.79±31.67.There was statistical difference between the r-AFS score. @
2.The Painful menstruation and the blood stasis symptom of 30 patients with pelvic endometriosis were reduced after TCM treatment.The dysmenorrheal score is lower then before.There was significant statistical difference between the two(P＜0.05). @
3.The expression of sICAM-1,VEGF、MMP-9、IL-6 in serum of patients with pelvic endometriosis were decreased after treatment with TCM for 3 months.There was statistical difference between the two(P＜0.05).But there was no statistical difference as compared with VEGF in the serum pre and post treatment(P＞0.05). @
Conclusion: @
1.The r-AFS score in the patients with pelvic endometriosis could be reduced by the treatment with Traditional Chinese Medicine Virtual Screening preoperatively,in these station,operation could be done successfully. @
2.The Painful menstruation and the blood stasis symptom of the patients with pelvic endometriosis could be improved with the TCM treatment. @
3.The expression of sICAM-1,VEGF,MMP-9,IL-6 in serum of patients with pelvic endometriosis were decreased after TCM treatment.We conjecture that mechanisms of TCM treatment on the patients with pelvic endometriosis,is concern with the 3A" and immunity.
引文
[1]张君娜,陈素琴,周娜静,等.AHSG和IL-6基因多态性与Ⅳ期卵巢子宫内膜异位囊肿的相关性研究.现代妇产科进展,2006;15:346-349.
[2]曹泽毅主编.中华妇产科学.第二版.北京:人民卫生出版社,2005:1481-1493.
[3]Ulukus M,Arici A.Immunology of endometriosis.Minerva Ginecol,2005:57(3):237.
[4]Tian zhigang,li kasheng.Interleukine-6 and dysimmunity diseases.Shanghai Journal of Immunology(in chinese),1990;10:189.
[5]Berquist A,Bruse C,Carlberg M,et al.Interleukin 1 beta,interleukin-6,and tumor necrosis factor-alpha in endometriotic tissue and in endometriurn.Fertil Steril,2001;75:489-495.
[6]朱剑飞,陈友国,等.子宫内膜异位症患者血清及腹腔液中白介素-6的临床意义.江苏医药杂志,2004:30(5):362-363.
[7]徐洪云,曹玉民,李建霞,等.IL-6与子宫内膜异位症发病关系的研究.现代妇产科进展,2007;16(1):57-59.
[8]曹立幸,韩冰,李同玺,等.活血化瘀、软件散结法对子宫内膜异位症IL-6影响.河南中医学院学报,2007;22(6):19-20.
[9]张军,万淑琼.黄芩素治疗子宫内膜异位症的作用研究.时珍国医国药,2007;18(4):895-897.
[10]张欣,吴令英,李小江,等.盆腔良性肿瘤伴血清CA125水平升高的临床意义.中华妇产科杂志,2005;40(3):178-182.
[11]余文辉,梁广佳,李忠新.血清肿瘤相关抗原125水平在子宫内膜异位症分期中的作用.国际检验医学杂志,2007;18(12):1070-1072.
[12]张玉蓉,徐莉,谢波.补肾活血法对子宫内膜异位症不孕患者EMAB、CA125的影响.中国医药学报,2004;19(5):319-320.
[13]具春花,金钟大,司徒仪.补肾活血方对内异症合并LUFS患者EMAB、CA125、PRL 的影响.江苏中医药,2007;39(9):22-24.
[14]Sidell N,Han SW,Parthasarathy S.Regulation and modulation of abnormal immune responses in eodoometriosis.Aon Ny Aead Sci,2002;955:159-173.
[15]Harada T,Enatsu A,Mitsunari M,el al.Role of cytokines in progression of endometriosis.Gynecol Obstet Invest,1999;47(11):34.
[16]Dan I,ebovic MD,ieller MD,et al.Immunobiology of endometriosis.Fetril Stefil,2001:75(1):761.
[17]Wu MH,ang BC,ee YC,et al.The differential expression of intercellular adhesion molecule-l(ICAM-1)and regulation by interferon-gamma during the pathogenesis of endometriosis.Am-J-Reprod-Immunol,2004:51(5):373-380.
[18]冷金花,郎景和,等.子宫内膜异位症患者血清可溶性细胞间粘附分子-1水平的检测.中华医学杂志,2002;82(3):189-190.
[19]王蓁,曹红,王萍,等.血清slCAM-1和CA125对卵巢子宫内膜异位囊肿的诊断价值.山东医药,2006:46(22):16-17.
[20]章旺,阎桂英,宿仕萍,等.可溶性细胞间粘附分子-1在子宫内膜异位症、盆腔炎腹腔液中的表达分析.中国妇幼保健,20061 2I:388-389.
[21]Chung H W,Wen Y,Chun S H,et al.Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase.3 mRNA expression in ectopic and eutopic endometfium in women with endometriosis:a ration for endometriotic invasiveness.Fertril Steril;2001;75(1):152-159.
[22]Hofmann UB,Westphal JR,Van Kraats AA,et aI.Expression of integrin alpha(v)beta(3)correlates with activation of membrane-type matrix metalloproteinase-1(MT-MMP1)and matrix etalloproteinase-2(MMP-2)in human melanoma cells in vitro and in vivo.Int J Cancer,2000:87(1):12-19.
[23]李艳,朗景和,王立杰,等.MMP-9及TIMP-1在子宫内膜异位症患者腹水及血清中的表达.现代妇产科进展,2005;14(14):293-296.
[24]邱晓红,韩丽英,李荷莲.血清基质金属蛋白酶-9诊断子宫内膜异位症术后复发的价值.中国免疫学杂志,2006;22:272-273.
[25]Chung H W,Wen Y,Chun S H,et al.Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-3 mRNA expression in ectopic and eutopic endometrium in women with endometriosis:a rationale for endometriotic invasiveness.Fertil Steril,2001;75(1):152-159.
[26]Mizumoto H,Saito T,Ashihara K,et al.Expression of matrix metalloproteinases in ovarian endometriomas:immunohisto-hemical study and enzyme immunoasasy.Life Sci,2002:1(3):259-273.
[27]黄艳辉,司徒仪.司徒仪治疗子宫内膜异位症经验.辽宁中医杂志,2006:33(1):16-17.
[28]Barcz E,Kaminski P,Marianowski L.Serum VEGF(vascular endothelial growth factor)concentration in patients with endometriosis.Ginekol Pol,2001;71(9):993.
[29]邓玉清,白骏,徐望明.子宫内膜异位症患者血管内皮生长因子的测定.中西医结合杂志,2004;13(14):1827-1828.
[30]徐红,欧奇志,况燕,等.动态检测子宫内膜异位症患者血清血管内皮生长因子的临床意义.实用妇产科杂志,2005;21(10):598-600.
[31]刘芳,陈必良,穆润华.子宫内膜异位症腹水内血管内皮生长因子及白细胞介素8的测定.江苏临床医学杂志,2002;6(2):122-448.
[32]Barcz E,Kaminski P,Marianowski L.VEGF concentration in peritoneal fluid of patients with endometriosis.Ginekol Pol,2001:72(5):442-448.
[33]王巧英,李兆艾.子宫内膜异位症患者血管内皮生长因子的检测及其临床意义.山西医学杂志,2006;35(6):500-502.
[34]中华医学会妇产科学分会子宫内膜异位症协作组.子宫内膜异位症的诊断与治疗规范.中华妇产科杂志,2007;42(9):645-648.
[35]周应芳.子宫内膜异位症的临床诊断和治疗.中华妇产科杂志,2005;40:67-70.
[36]冷金花,郎景和,杨佳欣.子宫内膜异位症的诊治进展.中华妇产科杂志,2000;35:53.
[37]李艺,祝洪澜,梁旭东,等.Ⅲ、Ⅳ期子宫内膜异位症患者保守性手术后的结局分析.中华妇产科杂志,2007;42(2):92-95.
[38]Parazzini F,Bertulessi C,Pasini A,et al.Determinants of short term recurrence rate of endometriosis.Eur J Obstet Gynecol Reprod Bioi,2005;121:216-219.
[39]李华军,冷金花,郎景和,等.子宫内膜异位症保守性手术后复发的相关因素分析.中华妇产科杂志,2005;40:13-16.
[40]周应芳.子宫内膜异位症药物治疗现状.继续医学教育,2005;19(5):27-28.
[41]梁雪芳,冉青珍,李燕钰.中药治疗对盆腔子宫内膜异位症患者盆腔状态的影响.时珍国医国药,2006;17(9):1767-1768.
[42]赵轩,刘俊丽,陈世荣,等.子宫内膜异位症手术治疗后复发相关因素的分析.中华妇产科杂志,2006;41(10):669-670.
[43]中国中西医结合学会妇产科专业委员会第三届学术会议修订.子宫内膜异位症、妊娠高血压综合征及女性不孕症的中西医结合诊疗标准.中西医结合杂志,1991;11(6):376.
[44]郎景和.子宫内膜异位症研究的任务与展望.中华妇产科杂志,2006;41(5):289-290.
[45]钱静.桂枝茯苓丸加味治疗子宫内膜异位症的临床研究.辽宁中医杂志,2000;27(4):170.
[46]向东方,梁雪芳,司徒仪.中医多途径疗法治疗子宫内膜异位症痛经51例分析.中医药学刊,2005;23(9):1616-1617.
[47]高月平.“消症饮”治疗子宫内膜异位症的实验研究.四川中医,2000;18(11):10.
[48]司徒仪,樊荫萍,潘华新.莪棱胶囊对大鼠实验性子宫内膜异位症作用机理探讨.中医杂志,2000;41(4):237.
[49]付金荣,董肇杨.血管加压素与子宫内膜异位症疼痛的关系及中药对其的影响.上海中医药杂志,2000;23(10):10-11.
[50]王本祥主编.现代中药药理学.天津科学技术出版社,1997:877-879.
[51]王如英,周琳.活血化瘀法治疗子宫内膜异位症的临床观察.中国中西医结合杂志,2004:24(3):258-259.
[52]吴凡,陈峰,康玉平.异位散对子宫内膜异位症家兔血液流变性及血管活性物质的影响.中国微循环,2003;7(6):355-356.
[53]司徒仪,梁雪芳,向东方,等.莪棱胶囊治疗子宫内膜异位症65例临床观察.中医杂志,1999:40(11):680-681.
[54]吴新华,鞠红梅,庞爱梅,等.康正消异颗粒对120例子宫内膜异位症患者免疫调节功能的影响.中医杂志,2003;44(90):680-681.
[55]吴如英,周琳.活血化瘀法治疗子宫内膜异位症的临床观察.中国中西医结合杂志,2004:24(3):258-259.
[56]刘艳巧,刘润侠.中药内异消对子宫内膜异位症大鼠腹腔液TNF-α影响.贵阳中医学院学报,2004;26(1):58-60.
[57]刘艳巧,刘润侠.补肾活血方对大鼠子宫内膜异位症血管生长因子等影响的研究.湖南中医学院学报,2004;24(1):16-18.
[58]梁雪芳,向东方.中医药综合疗法干预与子宫内膜异位症盆腔状况87例分析.陕西中医,2006;27(6):672-673.
[59]孙咏梅,金海红,徐应军,等.盆腔子宫内膜异位症相关因素分析.中国综合临床,2007:23(11):1035-1037.
[60]Roebuck,KA,Finnegan A.Regulation of intercellular adhesion molecules (CD54)gene ecpression.Leukoc Biol,1999;66:876.
[61]Donnez J,Somes P,Gilerot S,et al.Vasular endothelial growth factor(VEGF)in endometriosis.Human Reprod,1998:13:1686-1690.
[62]金海燕,王自能,卢凤昕,等.血管内皮生长因子在子宫内膜异位症发病中的作用.基础医学与临床,2005;25(3):257-259.
[2]曹泽毅主编.中华妇产科学.第二版.北京:人民卫生出版社,2005:1481-1493.
[3]Ulukus M,Arici A.Immunology of endometriosis.Minerva Ginecol,2005:57(3):237.
[4]Tian zhigang,li kasheng.Interleukine-6 and dysimmunity diseases.Shanghai Journal of Immunology(in chinese),1990;10:189.
[5]Berquist A,Bruse C,Carlberg M,et al.Interleukin 1 beta,interleukin-6,and tumor necrosis factor-alpha in endometriotic tissue and in endometriurn.Fertil Steril,2001;75:489-495.
[6]朱剑飞,陈友国,等.子宫内膜异位症患者血清及腹腔液中白介素-6的临床意义.江苏医药杂志,2004:30(5):362-363.
[7]徐洪云,曹玉民,李建霞,等.IL-6与子宫内膜异位症发病关系的研究.现代妇产科进展,2007;16(1):57-59.
[8]曹立幸,韩冰,李同玺,等.活血化瘀、软件散结法对子宫内膜异位症IL-6影响.河南中医学院学报,2007;22(6):19-20.
[9]张军,万淑琼.黄芩素治疗子宫内膜异位症的作用研究.时珍国医国药,2007;18(4):895-897.
[10]张欣,吴令英,李小江,等.盆腔良性肿瘤伴血清CA125水平升高的临床意义.中华妇产科杂志,2005;40(3):178-182.
[11]余文辉,梁广佳,李忠新.血清肿瘤相关抗原125水平在子宫内膜异位症分期中的作用.国际检验医学杂志,2007;18(12):1070-1072.
[12]张玉蓉,徐莉,谢波.补肾活血法对子宫内膜异位症不孕患者EMAB、CA125的影响.中国医药学报,2004;19(5):319-320.
[13]具春花,金钟大,司徒仪.补肾活血方对内异症合并LUFS患者EMAB、CA125、PRL 的影响.江苏中医药,2007;39(9):22-24.
[14]Sidell N,Han SW,Parthasarathy S.Regulation and modulation of abnormal immune responses in eodoometriosis.Aon Ny Aead Sci,2002;955:159-173.
[15]Harada T,Enatsu A,Mitsunari M,el al.Role of cytokines in progression of endometriosis.Gynecol Obstet Invest,1999;47(11):34.
[16]Dan I,ebovic MD,ieller MD,et al.Immunobiology of endometriosis.Fetril Stefil,2001:75(1):761.
[17]Wu MH,ang BC,ee YC,et al.The differential expression of intercellular adhesion molecule-l(ICAM-1)and regulation by interferon-gamma during the pathogenesis of endometriosis.Am-J-Reprod-Immunol,2004:51(5):373-380.
[18]冷金花,郎景和,等.子宫内膜异位症患者血清可溶性细胞间粘附分子-1水平的检测.中华医学杂志,2002;82(3):189-190.
[19]王蓁,曹红,王萍,等.血清slCAM-1和CA125对卵巢子宫内膜异位囊肿的诊断价值.山东医药,2006:46(22):16-17.
[20]章旺,阎桂英,宿仕萍,等.可溶性细胞间粘附分子-1在子宫内膜异位症、盆腔炎腹腔液中的表达分析.中国妇幼保健,20061 2I:388-389.
[21]Chung H W,Wen Y,Chun S H,et al.Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase.3 mRNA expression in ectopic and eutopic endometfium in women with endometriosis:a ration for endometriotic invasiveness.Fertril Steril;2001;75(1):152-159.
[22]Hofmann UB,Westphal JR,Van Kraats AA,et aI.Expression of integrin alpha(v)beta(3)correlates with activation of membrane-type matrix metalloproteinase-1(MT-MMP1)and matrix etalloproteinase-2(MMP-2)in human melanoma cells in vitro and in vivo.Int J Cancer,2000:87(1):12-19.
[23]李艳,朗景和,王立杰,等.MMP-9及TIMP-1在子宫内膜异位症患者腹水及血清中的表达.现代妇产科进展,2005;14(14):293-296.
[24]邱晓红,韩丽英,李荷莲.血清基质金属蛋白酶-9诊断子宫内膜异位症术后复发的价值.中国免疫学杂志,2006;22:272-273.
[25]Chung H W,Wen Y,Chun S H,et al.Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-3 mRNA expression in ectopic and eutopic endometrium in women with endometriosis:a rationale for endometriotic invasiveness.Fertil Steril,2001;75(1):152-159.
[26]Mizumoto H,Saito T,Ashihara K,et al.Expression of matrix metalloproteinases in ovarian endometriomas:immunohisto-hemical study and enzyme immunoasasy.Life Sci,2002:1(3):259-273.
[27]黄艳辉,司徒仪.司徒仪治疗子宫内膜异位症经验.辽宁中医杂志,2006:33(1):16-17.
[28]Barcz E,Kaminski P,Marianowski L.Serum VEGF(vascular endothelial growth factor)concentration in patients with endometriosis.Ginekol Pol,2001;71(9):993.
[29]邓玉清,白骏,徐望明.子宫内膜异位症患者血管内皮生长因子的测定.中西医结合杂志,2004;13(14):1827-1828.
[30]徐红,欧奇志,况燕,等.动态检测子宫内膜异位症患者血清血管内皮生长因子的临床意义.实用妇产科杂志,2005;21(10):598-600.
[31]刘芳,陈必良,穆润华.子宫内膜异位症腹水内血管内皮生长因子及白细胞介素8的测定.江苏临床医学杂志,2002;6(2):122-448.
[32]Barcz E,Kaminski P,Marianowski L.VEGF concentration in peritoneal fluid of patients with endometriosis.Ginekol Pol,2001:72(5):442-448.
[33]王巧英,李兆艾.子宫内膜异位症患者血管内皮生长因子的检测及其临床意义.山西医学杂志,2006;35(6):500-502.
[34]中华医学会妇产科学分会子宫内膜异位症协作组.子宫内膜异位症的诊断与治疗规范.中华妇产科杂志,2007;42(9):645-648.
[35]周应芳.子宫内膜异位症的临床诊断和治疗.中华妇产科杂志,2005;40:67-70.
[36]冷金花,郎景和,杨佳欣.子宫内膜异位症的诊治进展.中华妇产科杂志,2000;35:53.
[37]李艺,祝洪澜,梁旭东,等.Ⅲ、Ⅳ期子宫内膜异位症患者保守性手术后的结局分析.中华妇产科杂志,2007;42(2):92-95.
[38]Parazzini F,Bertulessi C,Pasini A,et al.Determinants of short term recurrence rate of endometriosis.Eur J Obstet Gynecol Reprod Bioi,2005;121:216-219.
[39]李华军,冷金花,郎景和,等.子宫内膜异位症保守性手术后复发的相关因素分析.中华妇产科杂志,2005;40:13-16.
[40]周应芳.子宫内膜异位症药物治疗现状.继续医学教育,2005;19(5):27-28.
[41]梁雪芳,冉青珍,李燕钰.中药治疗对盆腔子宫内膜异位症患者盆腔状态的影响.时珍国医国药,2006;17(9):1767-1768.
[42]赵轩,刘俊丽,陈世荣,等.子宫内膜异位症手术治疗后复发相关因素的分析.中华妇产科杂志,2006;41(10):669-670.
[43]中国中西医结合学会妇产科专业委员会第三届学术会议修订.子宫内膜异位症、妊娠高血压综合征及女性不孕症的中西医结合诊疗标准.中西医结合杂志,1991;11(6):376.
[44]郎景和.子宫内膜异位症研究的任务与展望.中华妇产科杂志,2006;41(5):289-290.
[45]钱静.桂枝茯苓丸加味治疗子宫内膜异位症的临床研究.辽宁中医杂志,2000;27(4):170.
[46]向东方,梁雪芳,司徒仪.中医多途径疗法治疗子宫内膜异位症痛经51例分析.中医药学刊,2005;23(9):1616-1617.
[47]高月平.“消症饮”治疗子宫内膜异位症的实验研究.四川中医,2000;18(11):10.
[48]司徒仪,樊荫萍,潘华新.莪棱胶囊对大鼠实验性子宫内膜异位症作用机理探讨.中医杂志,2000;41(4):237.
[49]付金荣,董肇杨.血管加压素与子宫内膜异位症疼痛的关系及中药对其的影响.上海中医药杂志,2000;23(10):10-11.
[50]王本祥主编.现代中药药理学.天津科学技术出版社,1997:877-879.
[51]王如英,周琳.活血化瘀法治疗子宫内膜异位症的临床观察.中国中西医结合杂志,2004:24(3):258-259.
[52]吴凡,陈峰,康玉平.异位散对子宫内膜异位症家兔血液流变性及血管活性物质的影响.中国微循环,2003;7(6):355-356.
[53]司徒仪,梁雪芳,向东方,等.莪棱胶囊治疗子宫内膜异位症65例临床观察.中医杂志,1999:40(11):680-681.
[54]吴新华,鞠红梅,庞爱梅,等.康正消异颗粒对120例子宫内膜异位症患者免疫调节功能的影响.中医杂志,2003;44(90):680-681.
[55]吴如英,周琳.活血化瘀法治疗子宫内膜异位症的临床观察.中国中西医结合杂志,2004:24(3):258-259.
[56]刘艳巧,刘润侠.中药内异消对子宫内膜异位症大鼠腹腔液TNF-α影响.贵阳中医学院学报,2004;26(1):58-60.
[57]刘艳巧,刘润侠.补肾活血方对大鼠子宫内膜异位症血管生长因子等影响的研究.湖南中医学院学报,2004;24(1):16-18.
[58]梁雪芳,向东方.中医药综合疗法干预与子宫内膜异位症盆腔状况87例分析.陕西中医,2006;27(6):672-673.
[59]孙咏梅,金海红,徐应军,等.盆腔子宫内膜异位症相关因素分析.中国综合临床,2007:23(11):1035-1037.
[60]Roebuck,KA,Finnegan A.Regulation of intercellular adhesion molecules (CD54)gene ecpression.Leukoc Biol,1999;66:876.
[61]Donnez J,Somes P,Gilerot S,et al.Vasular endothelial growth factor(VEGF)in endometriosis.Human Reprod,1998:13:1686-1690.
[62]金海燕,王自能,卢凤昕,等.血管内皮生长因子在子宫内膜异位症发病中的作用.基础医学与临床,2005;25(3):257-259.